CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-16 | OYLER JOHN Chief Executive Officer | Option exercise · Share Option (Right to Buy) 10b5-1 | −911,248 | 1,282,034 | ||
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Option exercise 10b5-1 | +35,605 | $100.04 | $3.6M | 35,605 |
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Option exercise 10b5-1 | +76,677 | $169.58 | $13.0M | 112,282 |
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Option exercise 10b5-1 | +4,275 | $160.40 | $686K | 116,557 |
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −6,067 | $310.02 | $1.9M | 110,490 |
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −41,336 | $310.92 | $12.9M | 69,154 |
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −12,857 | $311.71 | $4.0M | 56,297 |
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −48,657 | $312.86 | $15.2M | 7,640 |
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −7,640 | $313.58 | $2.4M | 0 |
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Option exercise · Share Option (Right to Buy) 10b5-1 | −462,865 | 1 | ||
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Option exercise · Share Option (Right to Buy) 10b5-1 | −996,801 | 9 | ||
| 2026-07-15 | OYLER JOHN Chief Executive Officer | Option exercise · Share Option (Right to Buy) 10b5-1 | −55,575 | 1,254,513 | ||
| 2026-07-14 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −4,139 | $303.07 | $1.3M | 8,122 |
| 2026-07-14 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −8,122 | $303.93 | $2.5M | 0 |
| 2026-07-14 | OYLER JOHN Chief Executive Officer | Option exercise 10b5-1 | +97,282 | $36.90 | $3.6M | 97,282 |
| 2026-07-14 | OYLER JOHN Chief Executive Officer | Option exercise 10b5-1 | +36,318 | $100.04 | $3.6M | 133,600 |
| 2026-07-14 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −39,090 | $305.02 | $11.9M | 94,510 |
| 2026-07-14 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −45,895 | $306.21 | $14.1M | 48,615 |
| 2026-07-14 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −40,781 | $306.93 | $12.5M | 7,834 |
| 2026-07-14 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −7,834 | $307.57 | $2.4M | 0 |
Page 8 of 71 · 1,406 trades